Intentional Self-harm F32 F33 F31 F34 F38 F39
Conditions
Interventions
Group 1: Patients with a primary diagnosis of depression, also in remission, are recruited. Beside demographic information, the following clinical data are obtained:
-Primary and secondary psychiatric
-Somatic diagnoses according to ICD-10
-Alcohol and drug abuse
-Pharmacological and psychological treatment
-Actions of intentional self-harm during the last six weeks and lifetime
-Suicide risk assessed according to rules and traditions at the centre.
The patients are also assessed through the Montgomery-Asberg Depression Scale. If actions of intentional self-harm occur, the de
Sponsors
Emotra AB
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: - In- and outpatients with a primary diagnosis of depression according to the ICD-10, also in remission; - Age: 18 years or older; - Gender: Any; - Signed Informed Consent.
Exclusion criteria
Exclusion criteria: - Patient’s dissent to participate in the study; - In cases of diagnosed or suspected dementia, the patient should to be excluded unless there is a special interest by the centre. If included, this condition must be noted; - In cases of known or suspected alcohol or other substance abuse, the patient has to be excluded unless there is a special interest by the centre. If included, this condition must be noted; - Patient’s inability to understand the instructions for the EDOR Test; - Serious problems of hearing.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| In the current observational study, the primary variables to be investigated are: - the prevalence of electrodermal hyporeactivity among the depressive patients, recruited and tested in the naturalistic setting of psychiatric clinics; - the incidence of actions of intentional self-harm i.e., suicide after, and suicide attempt before and after test during the one-year follow-up period. It is hypothesized that the EDOR Test will identify electrodermal hyporeactive depressed patients who in turns will show a higher suicidal proneness as indicated by intentional self-harm behaviours. The electrodermal reactivity is assessed through the EDOR Test when the patient is enrolled in the study. The occurrence of intentional self-harm during the one-year follow-up period will be assessed. Information on the method/s used will be obtained and the correspondent ICD-10 code/s will be assigned. The death intent of the worst suicide attempt (according to the patient) will be evaluated using the first eight items of the Beck Suicide Intent Scale. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcomes to be assessed will be: - the influence of secondary psychiatric diagnoses, antidepressive treatments, somatic diagnoses, as well as demographic characteristics, such as age and gender, on electrodermal reactivity levels; - possible traces of influence on the rate of suicide by the clinical use of the EDOR Test. Information on demographic characteristics, secondary psychiatric diagnoses, antidepressive treatments and somatic diagnoses will be collected immediately after patient’s enrolment. If possible, information on the suicide rates at the participating centres during the last two years before the beginning of the study and during the one-year follow-up period will be gathered. Suicide rates in the centres’ region (at county level or similar) will be also taken in consideration. | — |
Countries
France, Germany, Hungary, Italy, Poland, Portugal, Romania, Spain, Sweden
Contacts
Public ContactMarco Sarchiapone
Department of Medicine and Health Sciences, University of Molise
Outcome results
None listed